Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxytryptophan and a serotonergic agonist, mCPP.
The effects of naloxone, an opiate "pure" receptor antagonist, on the release of prolactin and corticosterone in the rat were studied following the administration of the serotonin precursor 5-hydroxytryptophan or the serotonin receptor agonist (-) -m-chlorophenylpiperazine. Naloxone clearly antagonizes the release of prolactin induced by 5-hydroxytryptophan administered alone at a dosage of 50 mg/Kg/b.wt. or at dosage of 30 mg/Kg/b.wt. preceded 60 minutes before injection by the administration of the serotonin uptake blocker fluoxetine. The opiate antagonist does not modify the increase in blood level of prolactin induced by (-) -m-chlorophenylpiperazine. Naloxone itself does not reduce the increase in plasma level of corticosterone induced by 5-hydroxytryptophan, 5-hydroxytryptophan+fluoxetine or (-)-m-chlorophenylpiperazine. The results suggest that endogenous opioids may be involved in the increase in serum level of prolactin induced by 5-hydroxytryptophan and also indicate the existence of different serotonergic neurotransmitter circuits capable of modulating the release of prolactin and corticosterone. A mutual interplay between serotonergic and opiate neurons may be involved in controlling the release of prolactin, but such an interplay does not seem to occur in the secretion of corticotrophin-releasing hormone.
D006916:5-Hydroxytryptophan / Q000494:pharmacology*; D000818:Animals; D003345:Corticosterone / Q000378:metabolism*; D005473:Fluoxetine / Q000494:pharmacology; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
D010879:Piperazines; D005473:Fluoxetine; D009270:Naloxone; D011388:Prolactin; D006916:5-Hydroxytryptophan; C015068:1-(3-chlorophenyl)piperazine; D003345:Corticosterone